Prestige Consumer Healthcare Inc. (PBH): Results of Operations and Financial Condition
Prestige Consumer Healthcare Inc. (PBH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991fy27-q1earningsr.htm EX-99.1 Document Exhibit 99.1 Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results • Q1 Revenue of $265.7 million up 6.5% versus prior year • Q1 Organic sales growth of 3.2%, exceeding expectations • Q1 Diluted EPS o
How this was made
The 30-second read
Why it matters
Traders can update PBH’s forward revenue, EPS, and cash-flow expectations based on the raised guidance ranges and the stated incremental revenue from Breathe Right and LaCorium.
Market read
A beat-and-raise quarter with explicit FY2027 guidance ranges and acquisition-related revenue/EPS contribution is a direct catalyst for PBH’s valuation.
What to watch
The filing notes Clear Eyes variability and acquisition integration and purchase accounting costs; execution risk could offset the guidance lift if synergies lag.
Background
SEC Form 8-K Item 2.02 reporting Prestige Consumer Healthcare’s fiscal 2027 first-quarter results and updated full-year outlook, including acquisition closures.
Ticker impact
Prestige Consumer Healthcare reported Q1 FY2027 results and raised its FY2027 revenue to $1,290 to $1,315 million and EPS to $4.55 to $4.65.
Likely positive bias for PBH as raised guidance and acquisition contribution support higher forward estimates, though debt refinancing may temper leverage concerns.
The filing includes specific Q1 revenue/EPS figures, acquisition closure timing, and an explicit raised full-year outlook range, all of which are actionable for traders repricing the stock.
Market effects
Signals continued consolidation and accretion from consumer healthcare brand acquisitions, potentially supporting sentiment for OTC-focused peers.
Limited direct regional spillover; primarily impacts US-listed consumer healthcare sentiment.
Acquisition-driven growth narrative may modestly influence global OTC brand M&A expectations.
Counterpoint
Reported GAAP net income declined year over year, and operating cash flow fell, so the raise may rely heavily on non-GAAP adjustments and working-capital timing.
Key entities
- issuerPrestige Consumer Healthcare Inc.
Reports Q1 FY2027 results, acquisition closures, and raises FY2027 revenue and adjusted EPS outlook.
- acquisitionBreathe Right acquisition
Closed late in the quarter; added incremental $6 million in revenue and is included in the raised outlook.
- acquisitionLaCorium Health acquisition
Closed in July; included in the raised outlook with expectations for Dermal Therapy growth.
- financing6.25% senior notes due 2034
Issued July 15, 2026 to refinance notes due in fiscal 2028, extending maturity to 2034.
